Company news from the 05/15/07 news brief

Share this article:
Bristol-Myers Squibb announced it would pay up to $192 million in a deal with Isis Pharmaceuticals to develop and market a new line of drugs for the prevention and treatment of cardiovascular disease. The drugs will target PCSK9, which helps regulate the amount of cholesterol in the bloodstream. Under the terms of the deal, Bristol-Myers Squibb will pay Isis a $15 million licensing fee for access to Isis’ PCSK9 research program, contribute at least $9 million to research funding over three years, and pay up to $168 million in fees for the initial drug development. Bristol-Myers Squibb will also pay Isis royalties on drug sales. While Bristol-Myers Squibb will fund the collaboration, both companies will be responsible for preclinical development.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, miaking for a tighter race with Amgen.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.